TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18362256

Group type: EXPERIMENTAL
Intervention: New interventions
Number of subjects: 216451

Group type: EXPERIMENTAL
Intervention: New treatments
Number of subjects: 216451

Group type: EXPERIMENTAL
Intervention: Statistically significant trials favoring new or standard treatments
Number of subjects: 216451
Study: 15768924

Group type: EXPERIMENTAL
Intervention: Union membership
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 1109
Study: 12208639

Group type: EXPERIMENTAL
Intervention: Achievement stress condition (mathematical and verbal challenge)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Social rejection stress condition (two social interaction challenges)
Number of subjects: 50
Study: 10333895

Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 133

Group type: COMPARATOR
Intervention: Baseline ACE inhibitor usage
Number of subjects: 133

Group type: COMPARATOR
Intervention: Baseline screening practices
Number of subjects: 133
Study: 8700963

Group type: EXPERIMENTAL
Intervention: High-protein strawberry yogurt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-protein sandwich
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-protein meals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-protein meals
Number of subjects: 0
Study: 1381639

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 0
Study: 6743785

Group type: EXPERIMENTAL
Intervention: 50 mg oral solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50 mg rectal suppository
Number of subjects: 30

Group type: COMPARATOR
Intervention: 50 mg intramuscular injection
Number of subjects: 30
Study: 31529007

Group type: EXPERIMENTAL
Intervention: Behavioral and pelvic floor muscle therapy combined with midurethral sling (n=209)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Sling alone (n=207)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 480
Study: 29116540

Group type: EXPERIMENTAL
Intervention: OCT20
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: OCT30
Number of subjects: 986

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 986
Study: 26004044

Group type: EXPERIMENTAL
Intervention: Modified exponential taper
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Normal exponential taper
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 25146509

Group type: EXPERIMENTAL
Intervention: Prone position ventilation combined with recruitment maneuvers (RM) for at least 10 hours
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (supine position)
Number of subjects: 116
Study: 21440398

Group type: EXPERIMENTAL
Intervention: Rectally insufflated CO2 with gadolinium-based tagging (A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rectally insufflated CO2 with bowel purgation (B)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rectally insufflated CO2 with barium-based tagging (C)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rectally insufflated CO2 with iodine-based tagging (D)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rectally insufflated CO2
Number of subjects: 14
Study: 18691937

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 17227715

Group type: EXPERIMENTAL
Intervention: Implantable carotid sinus baroreflex activating system (CSL and IPG)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Therapeutic electrical activation of the baroreflex system
Number of subjects: 17
Study: 15998163

Group type: EXPERIMENTAL
Intervention: Sibutramine plus structured WMP
Number of subjects: 501

Group type: COMPARATOR
Intervention: Only structured WMP
Number of subjects: 501
Study: 12409969

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8-16 mg once daily)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Enalapril (10-20 mg once daily)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 239

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 239
Study: 9816717

Group type: EXPERIMENTAL
Intervention: 4% lidocaine 6 ml at room temperature (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4% lidocaine 5 ml + 7% sodium bicarbonate 1 ml at room temperature (Group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4% lidocaine 5 ml + 7% sodium bicarbonate 1 ml warmed to 38 degrees C (Group D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline 6 ml (Group A)
Number of subjects: 80
Study: 7621841

Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mianserin 60-90 mg daily
Number of subjects: 12
Study: 1698185

Group type: EXPERIMENTAL
Intervention: Polychemotherapy (DTIC, vincristine, ftorafur, hydroxycarbamide) in clinical stage II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent chemotherapy (DTIC) in clinical stage I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polychemotherapy and Single-agent chemotherapy in clinical stage III
Number of subjects: 0
Study: 6458872

Group type: EXPERIMENTAL
Intervention: Imipramine (75 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zimelidine (200 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Zimelidine (100 mg/day)
Number of subjects: 10
Study: 31021313

Group type: EXPERIMENTAL
Intervention: Economic message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gain framed message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loss framed message
Number of subjects: 0
Study: 29101117

Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel (600 mg day 1; 150 mg days 2-7; then 75 mg daily)
Number of subjects: 17263

Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (300 mg day 1; then 75 mg daily)
Number of subjects: 17263

Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel
Number of subjects: 17263

Group type: COMPARATOR
Intervention: Standard-dose clopidogrel
Number of subjects: 17263
Study: 26317528

Group type: EXPERIMENTAL
Intervention: PCM plus TENS
Number of subjects: 241

Group type: COMPARATOR
Intervention: PCM
Number of subjects: 241
Study: 25135030

Group type: EXPERIMENTAL
Intervention: spring steel insole
Number of subjects: 33

Group type: COMPARATOR
Intervention: ordinary control insole
Number of subjects: 33
Study: 22254226

Group type: EXPERIMENTAL
Intervention: rhBMP‐2/ACS + Bio‐Oss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bio‐Oss
Number of subjects: 0
Study: 19443826

Group type: EXPERIMENTAL
Intervention: 12-week twice-weekly heart health program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Delayed-intervention control group
Number of subjects: 80
Study: 17439881

Group type: EXPERIMENTAL
Intervention: Normal-appearing white matter (NAWM) T(1) relaxation time
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Grey matter (GM) T(1) relaxation time
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Follow-up measurements of NAWM and GM T(1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patient NAWM peak-height
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control GM peak-height
Number of subjects: 23
Study: 15026868

Group type: EXPERIMENTAL
Intervention: Oral alcohol (0.3 g/kg in 250 mL water)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol (7.5 mg/kg/minute in 250 mL saline for 40 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (saline 250 mL infused for 40 minutes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both oral and intravenous alcohol
Number of subjects: 10
Study: 12611172

Group type: EXPERIMENTAL
Intervention: Intranasal administration of V2 vasopressin receptor agonist (1‐desamino‐8‐D‐arginin‐vasopressin)
Number of subjects: 0
Study: 11477842

Group type: EXPERIMENTAL
Intervention: Salvia Miltiorrhizae Composita (SMC) administered intravenously (16 ml) before NTG utilization
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (NTG only)
Number of subjects: 16
Study: 7666271

Group type: EXPERIMENTAL
Intervention: Experimental group using a cradle with motion, sound, tactile (containment), and reduced-light stimuli.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group using an identical cradle with no stimulus modulation features.
Number of subjects: 90
Study: 2572475

Group type: EXPERIMENTAL
Intervention: Ketoconazole orally (400 mg/day for 5 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nystatin vaginal pessaries (100,000 units twice/day for 7 days)
Number of subjects: 45
Study: 163931

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31317939

Group type: EXPERIMENTAL
Intervention: Early closure of ileostomy (in 8‐13 days after surgery)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Delayed closure of ileostomy (after 12 weeks)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Early closure of ileostomy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Delayed closure of ileostomy
Number of subjects: 65
Study: 29250537

Group type: EXPERIMENTAL
Intervention: Halometasone cream (15g daily for 7-14 days) in Group A
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Halometasone cream (20g daily for 7-14 days) in Group B
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Halometasone cream (30g daily for 7-14 days) in Group C
Number of subjects: 60
Study: 26151563

Group type: EXPERIMENTAL
Intervention: DayWhite (14% hydrogen peroxide whitening material containing potassium nitrate)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PreviDent 5000 Sensitive (desensitizing toothpaste)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Relief ACP (desensitizing gel)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: UltraEZ (desensitizing gel)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (30-minute treatment without any treatment material)
Number of subjects: 50
Study: 22315153

Group type: EXPERIMENTAL
Intervention: Sensodyne® Rapid Relief (8% strontium acetate, 1040 ppm sodium fluoride)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Colgate® Sensitive Pro‐ReliefTM daily (8% arginine, 1450 ppm sodium monofluorophosphate)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard toothpaste (1450 ppm sodium fluoride)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Water
Number of subjects: 28
Study: 21545981

Group type: EXPERIMENTAL
Intervention: Ezetimibe add-on therapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: No-ezetimibe group
Number of subjects: 109
Study: 19516150

Group type: EXPERIMENTAL
Intervention: Nutrition plus combination of aerobic and strength training (N + CAST)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nutrition only (N)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nutrition plus strength training (N + ST)
Number of subjects: 41
Study: 17650536

Group type: EXPERIMENTAL
Intervention: Integrated Psychological Therapy (IPT) program
Number of subjects: 56

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 56
Study: 15555002

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg twice daily
Number of subjects: 714

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714
Study: 11280651

Group type: EXPERIMENTAL
Intervention: Progressive dilatational tracheostomy (PDT)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Forceps dilatational tracheostomy (FDT)
Number of subjects: 127
Study: 9158083

Group type: EXPERIMENTAL
Intervention: Naloxone infusion at 2 mg/h (group 1, n = 7)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg i.v. bolus (group 2, n = 7)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both naloxone and metoclopramide (group 3, n = 6)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 8387963

Group type: EXPERIMENTAL
Intervention: Rufloxacin (400 mg loading dose on day 1, followed by 200 mg s.i.d.)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Ofloxacin (300 mg b.i.d.)
Number of subjects: 163
Study: 3549044

Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 21
Study: 31182400

Group type: EXPERIMENTAL
Intervention: Continuous antimicrobial prophylaxis
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 28902371

Group type: EXPERIMENTAL
Intervention: Pinless navigation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 100
Study: 27391321

Group type: EXPERIMENTAL
Intervention: Nurse-coordinated prevention programme (NCPP) consisting of four outpatient nurse clinic visits in the first 6 months after the index event, focusing on healthy lifestyles, biometric risk factors, and medication adherence, in addition to usual care.
Number of subjects: 754

Group type: COMPARATOR
Intervention: Usual care only (control group).
Number of subjects: 754
Study: 24819305

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) continued for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormone therapy (HT) discontinued for 2 years
Number of subjects: 0
Study: 23114452

Group type: EXPERIMENTAL
Intervention: Integrated care project 'Gesundes Kinzigtal'
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Control groups (two control groups)
Number of subjects: 1205
Study: 20102912

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4570

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 4570
Study: 18594002

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine dose-based models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentration-based exposure metrics for gemcitabine and its metabolites
Number of subjects: 0
Study: 15670986

Group type: EXPERIMENTAL
Intervention: l-carnitine 990 mg/day + 4 mL/day linseed oil (weeks 5-8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4 mL/day linseed oil + 990 mg/day l-carnitine (weeks 5-8)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: l-carnitine 990 mg/day (weeks 1-4)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4 mL/day linseed oil (weeks 1-4)
Number of subjects: 20
Study: 12145060

Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg/kg)
Number of subjects: 0
Study: 10022399

Group type: EXPERIMENTAL
Intervention: GnRHa plus GH (0.3 mg/kg x week s.c., 6 days weekly, for 2‐4 years)
Number of subjects: 20

Group type: COMPARATOR
Intervention: GnRHa alone
Number of subjects: 20
Study: 8574277

Group type: EXPERIMENTAL
Intervention: Dietary treatment (5.0 MJ/day diet) for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 0
Study: 2383532

Group type: EXPERIMENTAL
Intervention: Soya-bean fat diet
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Coconut fat diet
Number of subjects: 25
Study: 7417123

Group type: EXPERIMENTAL
Intervention: Moderate heat load (30 degrees C ET)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Severe heat load (35 degrees C ET)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comfort (21 degrees C ET)
Number of subjects: 9
Study: 31103125

Group type: EXPERIMENTAL
Intervention: Pilates Group (PG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 24
Study: 28349528

Group type: EXPERIMENTAL
Intervention: Playing-2-gether (P2G) intervention
Number of subjects: 175
Study: 26342560

Group type: EXPERIMENTAL
Intervention: Droxidopa 600 mg/day for 8 weeks
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 23157710

Group type: EXPERIMENTAL
Intervention: cCABG (conventional coronary artery bypass grafting with cardiopulmonary bypass and cardioplegic arrest‐induced I/R)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: cCABG
Number of subjects: 46

Group type: COMPARATOR
Intervention: OPCAB (off-pump coronary artery bypass grafting)
Number of subjects: 46
Study: 21372737

Group type: EXPERIMENTAL
Intervention: Music intervention (30 minutes of music)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual-care group (quiet rest)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Music intervention and Usual-care group
Number of subjects: 54
Study: 19750309

Group type: EXPERIMENTAL
Intervention: Forced-air blanket warmed at 38 degrees C for 30 minutes before anesthetic induction and up to 120 minutes after anesthetic induction (Gtotal)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Forced-air blanket warmed at 38 degrees C for 30 minutes before anesthetic induction (Gpre)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Forced-air blanket warmed at 38 degrees C after anesthetic induction up to 120 minutes (Gintra)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Gcont) with no warming
Number of subjects: 60
Study: 16962066

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50 mg
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 500 mg
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 15462688

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily
Number of subjects: 831
Study: 11704448

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg + Atropine 0.01 mg/kg
Number of subjects: 40
Study: 9042843

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: Both PTCA and CABG
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1829
Study: 7513403

Group type: EXPERIMENTAL
Intervention: AAIR pacing
Number of subjects: 12

Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 12
Study: 2963525

Group type: EXPERIMENTAL
Intervention: celiprolol (400 mg once daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 30165909

Group type: EXPERIMENTAL
Intervention: Mechanical chest compression device (LUCAS 2/3, Jolife AB/Stryker, Lund, Sweden)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Manual chest compressions
Number of subjects: 330
Study: 26803374

Group type: EXPERIMENTAL
Intervention: Reiki (GI)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo (GP)
Number of subjects: 256
Study: 24991908

Group type: EXPERIMENTAL
Intervention: Intervention (24 weekly group sessions led by community care workers)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Standard care (S)
Number of subjects: 390
Study: 21835497

Group type: EXPERIMENTAL
Intervention: Patient-centered online model
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-office visits
Number of subjects: 0
Study: 19269924

Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT) - 100 hours
Number of subjects: 32

Group type: COMPARATOR
Intervention: Computer games (CGs) control condition
Number of subjects: 32
Study: 18564693

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg twice daily for 7 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study: 15194207

Group type: EXPERIMENTAL
Intervention: Brief intervention with a consistent support person
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 127
Study: 11739071

Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (AAT) conducted in weekly 4-hour sessions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (matched patients)
Number of subjects: 10
Study: 9631993

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Fluconazole 300 mg
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Fluconazole 450 mg
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Fluconazole (all dosages)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study: 8052779

Group type: EXPERIMENTAL
Intervention: High-dose mitomycin C plus tegafur
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: High-dose mitomycin C plus UFT
Number of subjects: 136

Group type: COMPARATOR
Intervention: High-dose mitomycin C
Number of subjects: 136
Study: 3342553

Group type: EXPERIMENTAL
Intervention: Cefazolin (1 g before surgery, 500 mg every 8 hours for 6 doses)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cefamandole (2 g before surgery, 1 g every 8 hours for 6 doses)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 97
Study: 31941372

Group type: EXPERIMENTAL
Intervention: Low cholesterol efflux capacity
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Low sphingosine-1-phosphate levels
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Low apolipoprotein A-I levels
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: High HDL oxidative inflammatory index values
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: High HDL oxidative-inflammation index values
Number of subjects: 167
Study: 28083879

Group type: EXPERIMENTAL
Intervention: 18-month care coordination intervention delivered through community-based nonclinical care coordinators, supported by an interdisciplinary clinical team
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 303
Study: 26685937

Group type: EXPERIMENTAL
Intervention: Specimen-driven margin assessment
Number of subjects: 71

Group type: COMPARATOR
Intervention: Patient-driven margin assessment
Number of subjects: 71
Study: 25630840

Group type: EXPERIMENTAL
Intervention: Nutritional counselling plus Traditional Chinese Medicine (TCM) acupuncture
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nutritional counselling plus sham acupuncture
Number of subjects: 35